Subtype
Pancreatic Neuroendocrine Tumor
CI-CAN-00003588Explore in graph →
Non-malignant32 active trials
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003588Explore in graph →
Clinical trials
152 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 6 | Changhai HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05568017 | Neoadjuvant PRRT With Y-90-DOTATOC in pNET(NeoNet) | terminated | Phase 2 | 11 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02110563 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma |
| terminated |
| Phase 1 |
| 50 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY |
| 1 |
| Jul 11, 2024 |
| clinicaltrials |
| NCT04452396 | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | terminated | N/A | 7 | Barts & The London NHS TrustOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03947762 | Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.(PanNET) | terminated | — | 54 | IpsenINDUSTRY | 2 | Jun 14, 2021 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00730483 | Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors | terminated | N/A | 13 | Yale UniversityOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00466856 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | terminated | Phase 2 | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jun 11, 2026source: clinicaltrials